Shares of Sage Therapeutics jumped more than 5 percent in hours on Tuesday, based on the news that the FDA approved the first post-natal medicine called Zulresso. Zulresso is an intravenous injection used to treat a sometimes life-threatening postpartum depression, a major depressive episode that occurs after birth or leads to childbirth
"Women can experience thoughts of harming themselves or injuring their child. Postpartum depression can also prevent the relationship between mother and baby, says Tiffany Farhonie, acting director of the Department of Psychiatric Products at the FDA's Center for Evaluation and Research.
Zulresso will only be available through a limited program because of concerns about risks, including excessive sedation or sudden loss of consciousness during administration. This requires the drug to be administered by a healthcare provider in a certified healthcare facility.
Sage stocks have grown by more than 60% so far pending approval.